Clinical trial • Phase I • Oncology
Clinical trial in Metastatic or locally advanced solid tumors|Lung cancer|Head and neck cancer|Colon cancer|Gastric cancer|Esophageal cancer|Breast cancer|Ovarian cancer|Fallopian tube cancer|Primary peritoneal high-grade serous carcinoma
Phase I trial for Metastatic or locally advanced solid tumors|Lung cancer|Head and neck cancer|Colon cancer|Gastric cancer|Esophageal cancer|Breast cancer…
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Metastatic or locally advanced solid tumors|Lung cancer|Head and neck cancer|Colon cancer|Gastric cancer|Esophageal cancer|Breast cancer|Ovarian cancer|Fallopian tube cancer|Primary peritoneal high-grade serous carcinoma
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 07-08-2024
- First CTIS Authorization Date
- 09-09-2024
Trial design
Phase I trial across 1 site in Czechia.
- Target Sample Size
- 30
Eligibility
Recruits 30 No vulnerable population selected; no special consent or assent handling described in the record..
- Vulnerable Population
- No vulnerable population selected; no special consent or assent handling described in the record.
Recruitment
- Planned Sample Size
- 30
- Recruitment Window Months
- 42
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 30
Czechia
- Earliest CTIS Part Ii Submission Date
- 21-02-2024
- Latest Decision Or Authorization Date
- 01-10-2025
- Processing Time Days
- 590
- Number Of Sites
- 1
- Number Of Participants
- 30
Sites
- Site Name
- Masarykuv Onkologicky Ustav
- Department Name
- Dptm of Clinical Oncology
- Contact Person Name
- Radka Lordick Obermannová
- Contact Person Email
- radka.obermannova@mou.cz
Sponsor
Primary sponsor
- Full Name
- VUAB Pharma a.s.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Czechia
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)